Abstract #0457
MULTIMODAL PET-MRS INVESTIGATION OF GLUTAMATE-DEPENDENT NEURORECEPTOR PLASTICITY IN THE HEALTHY HUMAN BRAIN
Milan Scheidegger 1,2 , Alexander Fuchs 1 , Simon Ametamey 3,4 , Felix Kuhn 5 , Anass Johayem 5 , Alfred Buck 4,5 , Erich Seifritz 2,4 , and Anke Henning 1,6
1
Institute for Biomedical Engineering,
University and ETH Zurich, Zurich, Switzerland,
2
Department
of Psychiatry, Psychotherapy, and Psychosomatics,
University Hospital of Psychiatry Zurich, Zurich,
Switzerland,
3
Institute
of Pharmaceutical Sciences, University and ETH Zurich,
Zurich, Switzerland,
4
Neuroscience Center
Zurich, University and ETH Zurich, Zurich, Switzerland,
5
Division
of Nuclear Medicine, University Hospital Zurich, Zurich,
Switzerland,
6
Max
Planck Institute for Biological Cybernetics, Tbingen,
Germany
In this multimodal, double-blind, randomized,
placebo-controlled PET-MRS study in 20 healthy subjects,
we report a pharmacological modulation of
glutamate-dependent neuroreceptor plasticity in the
pregenual anterior cingulate cortex following the
administration of the NMDA-receptor antagonist ketamine.
In order to investigate the functional interplay between
the major excitatory neurotransmitter glutamate (Glu)
and the density of the metabotropic glutamate receptor
subtype 5 (mGluR5) we combined proton magnetic resonance
spectroscopy (1H-MRS) with positron emission tomography
(11C-ABP688-PET). Our findings complement previous
reports of increased glutamate release during ketamine
challenge by providing additional in vivo molecular
imaging evidence for ketamine-induced
neurotransmitter-receptor coupling.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
